Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
E-mail:
Web: www.cytokines.ru


  


Year 2018
1-4 issues

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:
Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2014, No. 3

Subscribe for 2019 year

Order this issue

Order PDF of this article

Practitioner Advisor

Number 3'2014

Influence of pathogenetic therapy of bronchial asthma with “Erespal” on the cellular composition and contents of cytokines in bronhoalveolar lavage

E.G.Murashov, S.V.Stolov, A.A.Totolian

To assess the severity of the inflammatory process in 80 patients with bronchial asthma, the content of several cytokines in bronhoalveolar lavage was examined by ELISA. Of these, in 40 patients, clinical effectiveness of erespal was studied and investigated its effects on cellular and cytokine contents of bronhoalveolar lavage. The exacerbation of asthma is accompanied by elevated levels of IL-4, IL-6, IL-8 and GM-CSF in bronhoalveolar lavage. In patients with atopic asthma, cytokine production was more intensive than in patients with mixed form of the disease. After a course of etiotropic therapy, cytokines levels fell, and IFNγ increased. The most pronounced changes were observed in the group of patients with atopic asthma taking erespal. The data suggest the reduction of duration of the disease and the terms of recovery of bronchial patency when applying erespal. (Cytokines and Inflammation. 2014. Vol. 13. № 2. P. .)

Keywords: bronchoalveolar lavage, cytokines, asthma, erespal.

Contents | Next article | Previous article


© 2007-2019 Cytokines and inflammation